Despite the benefits, they remain largely inaccessible for many in LMICs
GLP-1 RAs and SGLT2s are on the frontline—But can we afford them?GLP-1 receptor agonists and SGLT2 inhibitors are transforming type 2 diabetes care by improving heart, kidney, and stroke outcomes beyond glucose control, but their high cost and limited access raise concerns about equity.
> Read more